Rybrevant Den Europæiske Union - dansk - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - carcinom, ikke-småcellet lunge - antineoplastiske midler - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Tepmetko Den Europæiske Union - dansk - EMA (European Medicines Agency)

tepmetko

merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Tabrecta Den Europæiske Union - dansk - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Strefzap 8,75 mg/3 pust mundhulespray, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

strefzap 8,75 mg/3 pust mundhulespray, opløsning

reckitt benckiser a/s - flurbiprofen - mundhulespray, opløsning - 8,75 mg/3 pust

Strefzap honning og citron 8,75 mg/3 pust mundhulespray, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

strefzap honning og citron 8,75 mg/3 pust mundhulespray, opløsning

reckitt benckiser healthcare (scandinavia) a/s - flurbiprofen - mundhulespray, opløsning - 8,75 mg/3 pust

Avandamet Den Europæiske Union - dansk - EMA (European Medicines Agency)

avandamet

smithkline beecham plc - rosiglitazone, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - avandamet er indiceret til behandling af type 2-diabetes mellitus patienter, især overvægtige patienter:der ikke er i stand til at opnå tilstrækkelig glykæmisk kontrol ved deres maksimalt tolereret dosis af oral metformin alene. i triple oral behandling med sulphonylurea hos patienter med utilstrækkelig glykæmisk kontrol på trods af dobbelt oral behandling med deres maksimalt tolereret dosis af metformin og et sulphonylurea (se afsnit 4.